Jpmorgan Chase & CO Rani Therapeutics Holdings, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Rani Therapeutics Holdings, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 71 shares of RANI stock, worth $161. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 71 -0.0%

Holding current value

$161

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$3.13 - $7.85 $39,484 - $99,027	-12,615 Reduced 99.44%	71 $0
Q1 2024 May 10, 2024	BUY	$2.98 - $3.8 $26,784 - $34,154	8,988 Added 243.05%	12,686 $39,000
Q4 2023 Feb 12, 2024	SELL	$1.85 - $3.67 $1,370 - $2,719	-741 Reduced 16.69%	3,698 $12,000
Q3 2023 Nov 14, 2023	SELL	$2.17 - $4.44 $4,526 - $9,261	-2,086 Reduced 31.97%	4,439 $9,000
Q2 2023 Aug 11, 2023	BUY	$3.92 - $5.58 $19,921 - $28,357	5,082 Added 352.18%	6,525 $26,000
Q1 2023 May 11, 2023	BUY	$5.07 - $6.89 $3,315 - $4,506	654 Added 82.89%	1,443 $7,000
Q4 2022 Feb 13, 2023	SELL	$5.51 - $10.02 $3,350 - $6,092	-608 Reduced 43.52%	789 $5,000
Q3 2022 Nov 14, 2022	BUY	$8.23 - $12.4 $1,720 - $2,591	209 Added 17.59%	1,397 $13,000
Q2 2022 Aug 11, 2022	SELL	$8.0 - $14.25 $9,128 - $16,259	-1,141 Reduced 48.99%	1,188 $12,000
Q1 2022 May 11, 2022	SELL	$12.21 - $23.14 $22,673 - $42,970	-1,857 Reduced 44.36%	2,329 $31,000
Q4 2021 Feb 10, 2022	BUY	$16.09 - $35.0 $67,352 - $146,510	4,186 New	4,186 $68,000

Others Institutions Holding RANI

# of Institutions

Shares Held

5.78M

Call Options Held

2.5K

Put Options Held

2.2K

View Full List

About Rani Therapeutics Holdings, Inc.

Ticker RANI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,492,000
Market Cap $55.6M
Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed P...

More about RANI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Rani Therapeutics Holdings, Inc. Transaction History